

NIH176.001C1



#8
Election/
PATENT Ext(1mo.)

4.24.03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Scherf et al.)	Group Art Unit 1648
Appl. No.	:	10/087,013)	
Filed	:	February 21, 2002)	
For	:	IDENTIFICATION OF THE DOMAIN OF PLASMODIUM FALCIPARUM ERYTHROCYTE MEMBRANE PROTEIN 1 (PFEMP1) THAT MEDIATES ADHESION TO CHONDROITIN SULFATE A)	
Examiner	:	Lucas, Zachariah		

RECEIVED
APR 21 2003
TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

United States Patent And Trademark Office
PO Box 2327
Arlington, VA 22202

Dear Sir:

In response to the Restriction Requirement mailed February 11, 2003 in the above-identified application, Applicant responds as follows:

Restriction to one of the following groups was required under 35 USC 121:

Group I Claim 1, drawn to methods of detecting the concentration or expression level of an FCR.3varCSA gene or protein, classified in class 435, subclass 4.

04/16/2003 HGUTEMA1 00000027 10087013

01 FC:1251

110.00 0P

Appl. No. : 10/087,013
Filed : February 21, 2002

Group II Claim 2, drawn to methods of making a FCR3.varCSA disease state profile, classified in class 435, subclass 4.

Group III Claims 3-11 and 25-27, drawn to nucleic acids encoding FCR3.varCSA or fragments thereof, classified in class 536, subclass 23.1.

Group IV Claims 12-21, 24, 32, 33, drawn to the FCR3.varCSA protein and fragments thereof, classified in class 530, subclass 350.

Group V Claims 22 and 23, drawn to a method of making a FCR3.varCSA protein by inserting a cDNA encoding such into an expression vector, classified in class 435, subclass 69.1.

Group VI Claims 28-31 and 47 (in part), drawn to antibodies to the FCR3.varCSA protein or fragments thereof, classified in class 530, subclass 387.1.

Group VII Claims 34-36, drawn to methods of identifying FCR3.varCSA dependent adhesion to chondroitin sulfate A, classified in class 435, subclass 4.

Group VIII Claims 37-43, drawn to methods of detecting agents that modulate FCR3.varCSA dependent adhesion to CSA by attaching either CSA or FCR3.varCSA to a support, and contacting the support with either FCR3.varCSA or CSA, and contacting the support with the agent, classified in class 436, subclass 501.

Group IX Claim 44, drawn to methods of identifying an agent that modulates FCR3.varCSA dependent CSA adhesion by contacting a cell transfected with a construct comprising a nucleic acid sequence encoding a protein that binds CSA, classified in class 436, subclass 501.

Appl. No. : 10/087,013
Filed : February 21, 2002

Group X Claim 45, drawn to a method of identifying agents that interact with SEQ ID NO:2 or a fragment thereof, classified in class 435, subclass 501.

Group XI Claim 46, drawn to a method of preparing a therapeutic agent comprising an agent that modulates FCR3.varCSA dependant CSA adhesion and a pharmaceutically acceptable carrier, classified in class 514, subclass 1.

Group XII Claim 47, drawn to compositions comprising an agent that modulates FCR3.varCSA dependant CSA adhesion, classified in class 514, subclass 1.

Group XIII Claims 48-49, drawn to methods of treating or preventing maternal malaria by administering a nucleic acid complementary to SEQ ID NO:1 or fragments thereof, classified in class 536, subclass 24.5.

Group XIV Claims 50-55, drawn to methods of treating or preventing maternal malaria by administering FCR3.varCSA protein or fragment thereof, classified in class 514, subclass 1.

In response to the restriction requirement, Applicant elects Group IV, that is, Claims 12-21, 24, 32, 33.

CONCLUSION

In view of the foregoing, Applicant respectfully requests that this application be passed to issuance. If any points remain that can be resolved by telephone, the


Appl. No. : 10/087,013
Filed : February 21, 2002

Examiner is invited to contact the undersigned at the below-given telephone number.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 4/11/03

By: 

Nancy W. Vensko
Registration No. 36,298
Attorney of Record
Customer No. 20,995
(805) 547-5585

O:\DOCS\NWV\NWV-7797.DOC
040103



11648
PATENT

Case Docket No. NIH176.001C1
Date: April 11, 2003
Page 1

In re application of : Scherf et al.)
App. No. : 10/087,013)
Filed : February 21, 2002)
For : IDENTIFICATION OF THE)
DOMAIN OF PLASMODIUM)
FALCIPARUM)
ERYTHROCYTE)
MEMBRANE PROTEIN 1)
(PFEMP1) THAT MEDIATES)
ADHESION TO)
CHONDROITIN SULFATE A)
Examiner : Lucas, Zachariah)
Art Unit : 1648)

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: United States Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, on
April 11, 2003
(Date)

Nancy W. Vensko, Reg. No. 36,298

Nancy W. Vensko

UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. Box 2327
Arlington, VA 22202

Sir:

Transmitted herewith is an amendment in the above-identified application.

(X) An extension of time to respond for one month is hereby requested.

Time Extension Fee:

(X) one month (\$110 large entity)

The fee has been calculated as shown below:

CLAIMS AS FILED

CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
Total Claims 13 — 68		= 0 ×	\$18	= \$0
Independent Claims 8 — 30		= 0 ×	\$84	= \$0
If application has been amended to contain multiple dependent claim(s), then add			\$280	= \$0
Time Extension Fee				\$110
			TOTAL ADDITIONAL FEE FOR THIS AMENDMENT	\$110

- Return prepaid postcard.
- A check in the amount of \$110 is enclosed.
- Charge \$ to Deposit Account No. 11-1410.
- Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.
- Please use Customer No. 20,995 for the correspondence address.



Nancy W. Vensko
Registration No. 36,298
Attorney of Record
Customer No. 20,995
(805) 547-5580